VIEMED HEALTHCARE, INC. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Viemed Healthcare reported Q2 2026 net revenues of $78.1M (up 23.9% YoY, 3.6% sequentially), net income of $2.8M ($0.07/diluted share), and Adjusted EBITDA of $13.7M. The company raised full-year 2026 net revenue guidance to $314M–$320M (from $312M–$320M) and revised Adjusted EBITDA guidance to $64M–$68M (from $65M–$69M). During Q2, Viemed repurchased 530,802 shares for $5.1M at $9.65/share, repaid $2.2M of term debt, and grew ventilator patients to 12,635 (record high), PAP therapy patients to 37,825 (+44% YoY), and sleep resupply patients to 37,035 (+46.7% YoY). Cash position was $10.7M; long-term debt was $6.4M.
Why this rating
Strong revenue growth (24% YoY) and record patient census are encouraging; guidance raise is modest (0.1% low-end). Adjusted EBITDA margin compression (4% decline YoY despite 24% revenue growth) and declining free cash flow per diluted share raise profitability concerns. Material execution risk remains.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.